Track the Canadian Junior Mining Market at the speed of AI

Build a portfolio of Canadian junior mining companies on 6ix and get real-time updates the minute they announce something. Discover investor events, company profiles, and news in one place.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
51m ago	The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
51m ago	Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
51m ago	Max Power Mining Closes $25 Million Strategic Investment From Eric Sprott To Accelerate Commercial Evaluation at Lawson Max Power Mining Corp
1h ago	Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform Mach Conferences And Events Ltd.
2h ago	Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform Vanta Holdings Inc.

About

1.19USD+0.04 +3.48%

Closed • Updated at 04:51 GMT+00:00

Market Cap$4.53M

Volume70.7K

Beta3.74

RSI56.64

Health TechnologyPharmaceuticals: Major

Alzamend Neuro, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Recent Videos

DISCLOSED: 5 Stocks Wall Street Is Buying

DISCLOSED: 5 Stocks Wall Street Is Buying

Mar 26, 2026

My Concern After Alzamend Neuro's Nasdaq Filing

My Concern After Alzamend Neuro's Nasdaq Filing

Mar 24, 2026

ONL Begins EU Phase 2 GALAXY Trial | Alzamend Starts Lithium Brain Study

ONL Begins EU Phase 2 GALAXY Trial | Alzamend Starts Lithium Brain Study

Mar 17, 2026

My Key Question on Alzamend Neuro's Reverse Stock Split

My Key Question on Alzamend Neuro's Reverse Stock Split

Feb 27, 2026

Community Chat

Ask AI

Try asking